PLAINSBORO, N.J., March 29, 2025 /PRNewswire/ -- Novo Nordisk today presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic ® (semaglutide) injection 1 mg in ...

The combination of cagrilintide 2.4 mg and semaglutide 2.4 mg was superior to semaglutide alone for weight loss and HbA1c ...

An experimental combo drug from Novo Nordisk leads to more weight loss than semaglutide alone, according to late-stage trial data.

1. Bonaca M, Catarig AM, Houlind K, et al. The Effect of Once-weekly Subcutaneous Semaglutide on Functional Capacity in People with Type 2 Diabetes and Peripheral Artery Disease: Primary Results from ...

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...

Please provide your email address to receive an email when new articles are posted on . Twelve of 14 adults who underwent ReCET and received semaglutide maintained an HbA1c of less than 7.5% without ...

While the drug also previously succeeded in two obesity studies, it fell short of expectations at the time.

SHANGHAI (Reuters) -China's Innovent Biologics said on Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed. In this 26-week, double-blind trial of 72 adults, 36% who ...